Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$10.25-0.6%$12.39$7.21▼$23.98$2.46B0.835.84 million shs6.50 million shsANIPANI Pharmaceuticals$84.63+2.8%$76.50$56.71▼$99.50$1.85B0.46319,454 shs340,720 shsANVSAnnovis Bio$2.28+0.2%$2.25$1.42▼$5.50$79M1.261.44 million shs1.76 million shsQGENQiagen$33.98+0.1%$41.49$33.17▼$57.81$7.00B0.642.05 million shs1.46 million shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.57%-5.96%+11.53%-37.84%-56.77%ANIPANI Pharmaceuticals+5.27%+7.81%+14.04%+4.13%+16.63%ANVSAnnovis Bio+13.86%+21.81%+0.40%-12.15%+46.41%QGENQiagen-0.74%0.00%-17.22%-34.38%-24.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$10.25-0.6%$12.39$7.21▼$23.98$2.46B0.835.84 million shs6.50 million shsANIPANI Pharmaceuticals$84.63+2.8%$76.50$56.71▼$99.50$1.85B0.46319,454 shs340,720 shsANVSAnnovis Bio$2.28+0.2%$2.25$1.42▼$5.50$79M1.261.44 million shs1.76 million shsQGENQiagen$33.98+0.1%$41.49$33.17▼$57.81$7.00B0.642.05 million shs1.46 million shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.57%-5.96%+11.53%-37.84%-56.77%ANIPANI Pharmaceuticals+5.27%+7.81%+14.04%+4.13%+16.63%ANVSAnnovis Bio+13.86%+21.81%+0.40%-12.15%+46.41%QGENQiagen-0.74%0.00%-17.22%-34.38%-24.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.83Moderate Buy$25.67150.41% UpsideANIPANI Pharmaceuticals 2.88Moderate Buy$107.3326.83% UpsideANVSAnnovis Bio 2.25Hold$13.50491.07% UpsideQGENQiagen 2.50Moderate Buy$47.0938.56% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026QGENQiagen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$43.004/29/2026QGENQiagen JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$60.00 ➝ $45.004/29/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $38.004/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M4.78$0.65 per share15.76$2.01 per share5.10ANIPANI Pharmaceuticals$883.37M2.15$10.21 per share8.29$24.03 per share3.52ANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/AQGENQiagen$2.09B3.35$3.41 per share9.97$17.89 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6017.087.65N/A28.80%37.52%27.87%5/6/2026 (Estimated)ANIPANI Pharmaceuticals$78.34M$3.3625.199.54N/A8.87%27.97%9.70%5/8/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.40N/AN/AN/AN/A-159.43%-133.49%5/19/2026 (Estimated)QGENQiagen$424.88M$2.0216.8512.403.3820.33%14.56%8.62%5/6/2026 (Estimated)Latest ANIP, ADMA, ANVS, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026ANVSAnnovis Bio-$0.3950N/AN/AN/AN/AN/A5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28N/AN/AN/A$207.63 millionN/A5/6/2026Q1 2026ADMAADMA Biologics$0.1933N/AN/AN/A$139.98 millionN/A5/6/2026Q1 2026QGENQiagen$0.55N/AN/AN/A$499.20 millionN/A3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/A2/25/2026Q4 2025ADMAADMA Biologics$0.20$0.20N/A$0.20$139.80 million$139.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AQGENQiagen$0.260.77%N/A12.87%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.166.713.74ANIPANI Pharmaceuticals1.112.712.19ANVSAnnovis BioN/A5.805.80QGENQiagen0.443.903.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ANIPANI Pharmaceuticals8.10%ANVSAnnovis Bio20.80%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.16 million228.87 millionOptionableANIPANI Pharmaceuticals60022.41 million20.60 millionOptionableANVSAnnovis Bio334.65 million23.18 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableANIP, ADMA, ANVS, and QGEN HeadlinesRecent News About These CompaniesQiagen (QGEN) Gets a Buy from DZ BANK AG3 hours ago | theglobeandmail.comBrokerages Set Qiagen N.V. (NYSE:QGEN) PT at $53.64May 4 at 4:08 AM | americanbankingnews.comQiagen Cuts 2026 Outlook as QuantiFERON Immigration Testing Slumps Despite EPS MatchMay 3 at 10:02 PM | marketbeat.comQiagen (NYSE:QGEN) Upgraded at Zacks ResearchMay 2, 2026 | americanbankingnews.comHow The Qiagen (QGEN) Investment Story Is Shifting As Analysts Rework Their AssumptionsMay 1, 2026 | finance.yahoo.comQiagen (NYSE:QGEN) Upgraded by Zacks Research to "Hold" RatingMay 1, 2026 | marketbeat.comOngoing Investigation into Qiagen N.V. (QGEN): Contact Levi & Korsinsky About Potential FraudApril 30, 2026 | newsfilecorp.comNQiagen (NYSE:QGEN) Price Target Lowered to $45.00 at JPMorgan Chase & Co.April 30, 2026 | americanbankingnews.comQiagen Sets Date for Publication of 2025 Annual Financial ReportApril 30, 2026 | theglobeandmail.comBaird upgrades Qiagen NV (QGEN)April 30, 2026 | msn.comRobert W. Baird Upgrades Qiagen (NYSE:QGEN) to Strong-BuyApril 30, 2026 | marketbeat.comPictet Asset Management Holding SA Reduces Holdings in Qiagen N.V. $QGENApril 30, 2026 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for Qiagen (NYSE:QGEN) Stock PriceApril 29, 2026 | marketbeat.comCitigroup Lowers Qiagen (NYSE:QGEN) Price Target to $38.00April 29, 2026 | marketbeat.comQGEN stock slumps after-hours on guidance cut tied to weak TB test demandApril 29, 2026 | msn.comQiagen NV (QGEN) Q1 2026 Earnings Call Highlights: Navigating Mixed Sales with Strong ProfitabilityApril 29, 2026 | finance.yahoo.comQiagen (QGEN) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comQiagen (NYSE:QGEN) Sets New 12-Month Low - Should You Sell?April 29, 2026 | marketbeat.comQiagen N.V. (NYSE:QGEN) Receives Average Rating of "Hold" from AnalystsApril 29, 2026 | marketbeat.comQiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1April 29, 2026 | finance.yahoo.comQiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesApril 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Broadcom Hits $2 Trillion Market Cap as Google Reveals New AI ChipsBy Leo Miller | April 28, 2026ANIP, ADMA, ANVS, and QGEN Company DescriptionsADMA Biologics NASDAQ:ADMA$10.25 -0.06 (-0.58%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$10.30 +0.05 (+0.47%) As of 05/5/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$84.63 +2.31 (+2.81%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$86.08 +1.46 (+1.72%) As of 05/5/2026 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$2.28 +0.00 (+0.18%) Closing price 05/5/2026 03:59 PM EasternExtended Trading$2.28 -0.01 (-0.39%) As of 05/5/2026 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Qiagen NYSE:QGEN$33.98 +0.02 (+0.07%) Closing price 05/5/2026 03:59 PM EasternExtended Trading$34.05 +0.07 (+0.19%) As of 05/5/2026 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
